RT Journal Article
SR Electronic
T1 Response to Tocilizumab in Rheumatoid Arthritis Is Not Influenced by the Body Mass Index of the Patient
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 580
OP 584
DO 10.3899/jrheum.140673
VO 42
IS 4
A1 Pers, Yves-Marie
A1 Godfrin-Valnet, Marie
A1 Lambert, Joseph
A1 Fortunet, Clémentine
A1 Constant, Elodie
A1 Mura, Thibault
A1 Pallot-Prades, Béatrice
A1 Jorgensen, Christian
A1 Maillefert, Jean-Francis
A1 Marotte, Hubert
A1 Wendling, Daniel
A1 Gaudin, Philippe
YR 2015
UL http://www.jrheum.org/content/42/4/580.abstract
AB Objective. To assess the relationship between the body mass index (BMI) and the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods. We conducted a retrospective study in 222 patients with RA followed by 5 centers. The European League Against Rheumatism response was evaluated at 6 months. Univariate and multivariate logistic regressions were performed. Results. No significant association between the BMI and the response to TCZ at 6 months was found after adjustment for potential confounding factors (adjusted OR 0.45, 95% CI 0.16–1.24, p = 0.13 and OR 1.19, 95% CI 0.31–4.48, p = 0.78 for BMI 25–30 kg/m2 and BMI > 30 kg/m2, respectively, compared to BMI < 25 kg/m2). Conclusion. Response to TCZ in patients with RA is not influenced by the baseline BMI, in contrast to anti-tumor necrosis factor drugs.